Cardiac side effects of anticancer treatments: New mechanistic insights

被引：11
作者：
Carrie Geisberg
Laura Pentassuglia
Douglas B. Sawyer
机构：
[1] Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN 37232
[2] Department of Biomedicine, University Hospital of Basel, 4031 Basel
来源：
Current Heart Failure Reports | 2012年 / 9卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Adriamycin; Anthracycline; Cardiac progenitor cell; Cardiac toxicity; Cardio-oncology; Daunorubicin; Doxorubicin; Erbb2; Heart failure; Herceptin; Sorafenib; Sunitinib; Therapy; Trastuzumab; VEGF;
D O I：
10.1007/s11897-012-0098-4
中图分类号：
学科分类号：
摘要：
Damage to heart cells leading to heart failure is a known complication of well-established cancer therapies including anthracycline antibiotics and radiation therapy, and the cardiovascular complications of these therapies has been controlled in large part through dose limitations and modifications of delivery methods. Recent research into the cellular and molecular mechanisms for the cardiovascular effects of these therapies may lead to other cardioprotective strategies that improve effectiveness of cancer treatments. Newer cancer therapies that have been developed based upon specifically targeting oncogene signaling also have been associated with heart failure. Rapid development of a detailed understanding of how these agents cause cardiac dysfunction promises to improve outcomes in cancer patients, as well as stimulate concepts of cardiovascular homeostasis that will likely accelerate development of cardiovascular therapies. © Springer Science+Business Media, LLC 2012.
引用
收藏
页码：211 / 218
页数：7
相关论文
共 93 条
[1]  
Arcamone F., Di Marco A., Gaetani M., Et al., Isolation and antitumor activity of an antibiotic from streptomycse, G Microbiology, 9, (1961)
[2]  
Eschenhagen T., Force T., Ewer M.S., Et al., Cardiovascular side effects of cancer therapies: A position statement from the heart failure association of the european society of cardiology, Eur J Heart Fail, 13, 1, pp. 1-10, (2011)
[3]  
Von Hoff D.D., Layard M.W., Basa P., Et al., Risk factors for doxorubicin-induced congestive heart failure, 91, 5, pp. 710-7, (1979)
[4]  
Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., Suter T.M., Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity, Circulation, 105, 13, pp. 1551-1554, (2002)
[5]  
Sawyer D.B., Fukazawa R., Arstall M.A., Kelly R.A., Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane, Circulation Research, 84, 3, pp. 257-265, (1999)
[6]  
Lambertenghi-Deliliers G., Zanon P.L., Pozzoli E.F., Et al., Myocardial Injury Induced by a Single Dose of Adriamycin: An Electron Microscopic Study, 62, 5, pp. 517-28, (1976)
[7]  
Unverferth D.V., Magorien R.D., Unverferth B.P., Et al., Human Myocardial Morphologic and Functional Changes In The First 24 Hours After Doxorubicin Administration, 65, 11-12, pp. 1093-7, (1981)
[8]  
Lipshultz S.E., Rifai N., Sallan S.E., Lipsitz S.R., Dalton V., Sacks D.B., Ottlinger M.E., Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury, Circulation, 96, 8, pp. 2641-2648, (1997)
[9]  
Yoshida M., Shiojima I., Ikeda H., Et al., Chronic doxorubicin cardiotoxicity is mediated by oxidative dna damage-Atm-p53-Apoptosis pathway and attenuated by pitavastatin through the inhibition of rac1 activity, J Mol Cell Cardiol, 47, 5, pp. 698-705, (2009)
[10]  
Ward D.C., Reich E., Goldberg I.H., Base specificity in the interaction of polynucleotides with antibiotic drugs, Science, 149, 3689, pp. 1259-63, (1965)
12345678910